The quantitative imaging of myocardial blood flow (MBF) has been gaining momentum in recent years, as is the use of F-18 flurpiridaz, which has been shown to reveal a clear demarcation of disease in patients with CAD, according to a first-in-human quantitative imaging study published July 28 in the Journal of Nuclear Medicine . {read more}